Posted by DendreonOpinion on January 21st, 2012
In the past couple of weeks DNDN has been the recipient of a modest increase in share price. Doubling in value is still modest when compared with this summers over $30 per share.
Dendreon’s chief product, in fact their only product on the market is Provenge. The share price dropped in the summer due to not meeting the sales goals the company had set. Officials said doctors where finding it difficult to obtain reimbursement for Provenge.
Seeking Alfa, a pharmaceutical stock newsletter, recently said that the problem over reimbursement seems to have been solved. If that is the case then one must ask why have prescriptions for Provenge gone on a binge? Granted, sales have increased, but nothing like one would expect if doctors believed in it efficacy. Hundreds of thousand of prostate cancer sufferers are opting or being advised to take some other treatment, leaving Provenge lab cubicals redundant.
What is the problem? Who knows, but the legacy of Dendreon and Provenge seems to be continuing down the route of mystery, manipulation and lack of profit.
Are the major pharmaceutical companies still out to break the upstart Dendreon? They do not seem to be interested in buying out the company.
What about the weeks to come? More suffering by patients and stock holders is on the way.
Posted by DendreonOpinion on June 23rd, 2011
Cancer sufferers and investors can be grateful that Dendreon (DNDN) is positioned for a nice run up. There is just too much news in the pipe for the next few months that it would take a catastrophy to thwart a rise in the share price of the maker of Provenge the world’s first cancer vaccine.
- Provenge should have approval from the CMS within a matter of weeks, which will open Provenge to a wider population that could not afford it in some states.
- New stations at the New Jersey facility (NJ) plus new plants (Georgia and California) can only mean new revenue.
- Dendreon recently announced three new trials. If previous Provenge trials are any indication, investors and the press can expect string of progress reports and intermediate results.
- Dendreon has cash.
Dendreon current share price ($38.70) is far below the value in the company and its future. Dendreon has a long history of being manipulated, but the weight of forward motion by the company will soon over power the short players.Other related articles:
Posted by DendreonOpinion on May 28th, 2011
Dendreon is the maker of Provenge, the world’s first cancer vaccine and been on the short end on of the greatest stock maneuvering or manipulating Wall Street has ever witnessed.
Recently, the stock has been on a decided run-up. There is still a lot of news to come out, not that they would hide the news, but the PR department at the home office has never been known for being aggressive with reporting. But, this is a research and development company. Dendreon scientists are working, as you read this, to come up with new uses for the Antigen Delivery Cassette™ Technology which is Dendreon’s proprietary approach for antigen modification. They are also conducting analysis of Provenge’s on-going medical trails to seek out ways in which to apply for broadening of the label, especially for those not nearly as severe as those described in the present labeling. There a two other products in phase 2 and phase 3 clinical trials. Two others are in pre-clinical phases. At any moment some new find could be annouced.
Dendreon has found so much demand for Provenge that it has not yet been able to offer it to everyone who wants it. That will change dramatically by the end of this year with new labs coming on line in California and Georgia. Every new station will start production immediately to meet the demand.
Dendreon’s PPS (price per share) has been on the rise in recent months. At 42.38, DNDN is at heights it has not seen for six months. A chart of the past five days shows it on a modest rise each day, established a solid, upward trend.
There is a lot of news ahead and it could start rolling in any minute. The next scheduled news event is in two weeks at the Goldman Sachs Annual Global Healthcare Conference in Rancho Palos Verdes, California. Dendreon’s presentation will be webcaste at at 2:00 p.m. PTon June the 7th.
Lets not forget the raising number of prostate cancer patients who are living longer and suffering less through the Provenge treatment.
Other related articles:
Posted by DendreonOpinion on April 29th, 2011
The price per share of Dendreon is up more than 30% in the past 3o days. After sitting still or moving lower for almost a year, the maker of Provenge, the first cancer vaccine seems to streaking toward its true value.Provenge offers hope where there was little or no hope for severe prostate cancer sufferers.
Hundreds of patients have begun treatment since Provenge was approved by the FDA in April of 2010 and the number of doctors recommending Provenge treatment is increasing.One of the major, recent hurdles for Dendreon is sufficient production of Provenge to meet the demand. This is changing now with added capacity at the NJ plant and two other locations (Georgia and California) rapidly closing in initial production of the vaccine.
These are great days for investors and patients. Well overdue.
Posted by DendreonOpinion on February 28th, 2011
Georgia, Quick Start, and Dendreon connection is worth millions in cash with a hope of jobs.
It is unclear all the thinking that went into Dendreon deciding to build manufacturing lab in Union City, Georgia, but it is obvious that the incentives they were given must have played a major role. The Quick Start training film productions (the maiden voyage of the Georgia based company into the biotechnology field) and Hope grant for further education of employees is a package worth more than $8 million. The State of Georgia added nearly $11 million in additional incentives.
The state was not being altruistic, they are expecting at least 550 jobs. Some positions have already been filled and many more are currently listed.
Prostate cancer sufferers and investors also have a stake in Dendreon’s Georgia plant. Currently Dendreon’s production falls short of the national demand for its vaccine, Provenge. The Union City facility will boost its production. Investors have been longing for completion of the new digs and they should be rewarded generously when that day comes.
(Quick Start has expanded far beyond its training partnership with Dendreon, entering into education films for best practices and regulation systems in biotechnology and healthcare fields.)
Quick Start is also being used OSHA to train its personnel.
Othere Georgia, Quick Start, Dendreon connection links:
The Glow of Knowlege
The Social Media Presence of a Prostate Cancer Vaccine
Provenge Ranks High in 4 Year End Lists
Posted by DendreonOpinion on February 9th, 2011
Every new treatment or drug struggles to be adopted by treatment centers. This is especially true when it comes to cancer treatments. Yet, Provenge is moving into more hospitals and cancer treatment centers programs. This week two new, major centers added Provenge. Cancer treatment centers seldom desire to be the first to adopt a new treatment. Provenge has now been on the market for almost a year. Hospitals have been watching the results and demand of Provenge at those centers who were the first to adopt the prostate cancer treatment and they are now beginning to add Provenge to the options they offer to their patients.
Rosswell Park Cancer Institute in Buffalo, New York and Mount Sinai Comprehensive Cancer Center in Miami Beach, Florida have brought the total of sites offering Provenge to more than fifty.
On the competitions front, some scientists and analysts have viewed Zibotentan as possibly vying to upstage Provenge at treatment centers in the future, but AstraZeneca abruptly stopped trials of the drug this week due to poor trial results.
Expect Provenge to be offered at more and more centers over the next few months.
Posted by DendreonOpinion on January 24th, 2011
Provenge is the first FDA approved cancer vaccine. Dendreon, the maker of Provenge, a vaccine for treatment of advanced prostate cancer, has several other vaccines in the pipeline to treat other forms of cancer. Once they are fully ramped up to deliver enough Provenge to cover the high demand, they will have sufficient funds to expand their trials on vaccines in the pipeline.
Dendreon is not alone in cancer vaccine research. The follow 4 articles discuss advancements in cancer vaccine research:
Cancer Research Institute Announces Second Investment From Its Cancer Vaccine Acceleration Fund To Enable Manufacture Of Powerful Immune Stimulant - from Medical News Today, Jan. 24, 2011
The Latest on the Journey toward Human Breast Cancer Vaccine Development - from What’s Up in the Neighborhood, Jan. 17, 2011
New Vaccine for Brain Cancer – from Bio-Medicine
Vaccine approved for anal cancer prevention – from L.A. Times, Dec. 23, 2010
Related Articles from Dendreon Opinion:
Provenge User Gives Advice to Prostate Cancer Sufferers
Recent Reports Favoring Provenge
Doctors Speak Out on Provenge and Prostate Cancer
Posted by DendreonOpinion on December 21st, 2010
Dendreon Corporation’s stockholders have witnessed DNDN share price rise and fall over the past several years. Though DNDN shares are currently priced well above its historical lows, many feel that is well below where it should be. Over the years many pundits and serious researchers have written articles in an attempt to identify individuals and institutions who might have manipulated DNDN stock and caused investors to loose millions of dollars and many prostate cancer sufferers to loose their lives. Below is a list of six articles written over the past two years on Dendreon’s share price manipulation:
Posted by DendreonOpinion on December 20th, 2010
Dendreon’s Provenge is definitely a major breakthrough in the science and medical world. Without a doubt it is very important new option for Prostate Cancer sufferers. At the end of the year Provenge continues to collect recognition for its accomplishments in 2010. Here is the list of honors so far:
- Top Cancer News Stories for 2010
- Popular Science’s list of Best of What’s New in 2010
- Exconomy Top Innovations of 210
- Wall Street Journal’s Best of the Health Blog 2010
Posted by DendreonOpinion on December 17th, 2010
I just came across this first hand article from a gentleman well into his Provenge treatment.
He tells PC sufferers how to prepare for surgery as well as how best to care for themselves after treatment. The entire treatment may cost him less than $3000.
The article begins: “I had my third and final Provenge treatment last week and wanted to provide the group with several practical suggestions in case any of you are considering it. Overall, the treatments went well, but I did experience some chills and shivers near the end of the second infusion and several hours after the third treatment. Benadryl was the solution to this problem.” To read more click here.